Trial reportCancer2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Trial report in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Performance of Survival Prediction Tools in Patients With Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.Journal of surgical oncology · 2026Pooled it
- Trial
- Duration-dependent effects of adjuvant imatinib on recurrence-free and overall survival after resection of gastrointestinal stromal tumors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Primary extra-gastrointestinal stromal tumor of the gallbladder: A case report.World journal of gastroenterology · 2025Article
- Development and validation of a prognostic nomogram for gastric GIST patients under 65 years of age.Discover oncology · 2025Article
- Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective.JCO global oncology · 2023Article
- Review
- Microvessel density in patients with gastrointestinal stromal tumors: A systematic review and meta-analysis.World journal of methodology · 2023Article
- Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor.Journal of personalized medicine · 2023Article
- Risk stratification of gastrointestinal stromal tumors by Nanostring gene expression profiling.Journal of cancer research and clinical oncology · 2022Article
- Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.Frontiers in nutrition · 2022Article
- Malignant Gastrointestinal Stromal Tumor of Rectum: A Case Report and Review of Literature.Surgery journal (New York, N.Y.) · 2022Article
- Rectovaginal extragastrointestinal stromal tumour (EGIST): an additional entity to be considered in the differential diagnosis of tumours of the rectovaginal septum.BMJ case reports · 2021Review
- A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Progress in determining response to treatment in gastrointestinal stromal tumor.Expert review of anticancer therapy · 2020Review
- Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study.Journal of gastrointestinal cancer · 2019Article
- Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA.Langenbeck's archives of surgery · 2019Article
- Defining Tumor Rupture in Gastrointestinal Stromal Tumor.Annals of surgical oncology · 2019Article
- Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors.Annals of gastroenterological surgery · 2019Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 5 countries.
Funding
Abstract
backgroundLittle is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib.
methodsRisk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months.
resultsFive factors (high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months) were independently associated with unfavorable recurrence-free survival (RFS) in a multivariable analysis in the SSGXVIII cohort. A risk score based on these 5 factors had a concordance index with GIST recurrence of 78.9%. When a simpler score consisting of the 2 strongest predictive factors (mitotic count and tumor site) was devised, the groups with the lowest, intermediate high, and the highest risk had 5-year RFS of 76.7%, 47.5%, and 8.4%, respectively. Both scores were strongly associated with RFS in the validation cohort (P < .001 for each comparison).
conclusionsThe scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.